Further Responses in azer-cel Phase 1b Trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The trial continues to show promising results across multiple B-cell malignancies, with patient enrollment ongoing at various sites in the U.S. and Australia. These findings contribute to the growing clinical evidence supporting azer-cel's effectiveness in treating patients with significant unmet medical needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Imugene
- Notification of cessation of securities - IMU
- Application for quotation of securities - IMU
- Notice of Annual General Meeting/Proxy Form
- Dr John Le Gall appointed Chief Medical Officer
- azer-cel BTKi Cohort Reports new Complete & Partial Response
Later from Imugene
- Quarterly Activities/Appendix 4C Cash Flow Report
- Positive amendments to Convertible Notes
- Imugene selected for Poster Presentation at 2026 ASH Meeting
- AGM Presentation
- Results of 2026 Annual General Meeting
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene